19.21

2.17% -0.375

Tandem Diabetes Care Inc (TNDM)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt TNDM? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$19.59

Offen:

$19.62

24-Stunden-Volumen:

991.77K

Relative Volume:

0.53

Marktkapitalisierung:

$1.31B

Einnahmen:

$1.01B

Nettoeinkommen (Verlust:

$-204.71M

KGV:

-6.2592

EPS:

-3.0691

Netto-Cashflow:

$-29.67M

1W Leistung:

-21.83%

1M Leistung:

-24.27%

6M Leistung:

+57.83%

1J Leistung:

+0.00%

1-Tages-Spanne:

$18.89

$20.30

1-Wochen-Bereich:

$18.89

$25.05

52-Wochen-Spanne:

$9.98

$29.65

Tandem Diabetes Care Inc Stock (TNDM) Company Profile

Firmenname

Tandem Diabetes Care Inc

Sektor

Healthcare (1115)

Branche

Medical Devices (143)

Telefon

858-366-6900

Adresse

12400 HIGH BLUFF DRIVE, San Diego, CA

Mitarbeiter

2,500

Twitter

@tandemdiabetes

Nächster Verdiensttermin

2024-11-06

Neueste SEC-Einreichungen

TNDM's Discussions on Twitter

Compare TNDM vs ABT, SYK, MDT, BSX, EW

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
TNDM Tandem Diabetes Care Inc	19.18	1.34B	1.01B	-204.71M	-29.67M	-3.0691
ABT Abbott Laboratories	102.57	177.03B	44.33B	6.50B	7.40B	3.717
SYK Stryker Corp	327.82	124.89B	25.12B	3.25B	4.28B	8.3984
MDT Medtronic Plc	86.71	110.08B	35.48B	4.64B	5.41B	3.582
BSX Boston Scientific Corp	62.45	93.53B	20.08B	2.89B	3.66B	1.9391
EW Edwards Lifesciences Corp	80.07	45.84B	6.07B	1.06B	1.34B	1.8063

Tandem Diabetes Care Inc Stock (TNDM) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-03-19	Hochstufung	Truist	Hold → Buy
2026-03-17	Hochstufung	Piper Sandler	Neutral → Overweight
2026-02-23	Hochstufung	Lake Street	Hold → Buy
2026-02-20	Hochstufung	BofA Securities	Underperform → Neutral
2026-01-27	Fortgesetzt	TD Cowen	Buy
2025-12-16	Hochstufung	Robert W. Baird	Neutral → Outperform
2025-10-21	Fortgesetzt	Stifel	Hold
2025-09-08	Eingeleitet	Oppenheimer	Outperform
2025-08-12	Hochstufung	Citigroup	Sell → Neutral
2025-08-07	Herabstufung	Piper Sandler	Overweight → Neutral
2025-07-09	Herabstufung	Citigroup	Neutral → Sell
2025-06-16	Eingeleitet	Truist	Hold
2025-04-10	Eingeleitet	Mizuho	Neutral
2025-03-05	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2025-03-04	Herabstufung	Citigroup	Buy → Neutral
2025-03-03	Herabstufung	Wells Fargo	Overweight → Equal Weight
2025-02-28	Herabstufung	Bernstein	Outperform → Mkt Perform
2024-12-02	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2024-11-06	Eingeleitet	Bernstein	Outperform
2024-10-04	Eingeleitet	Goldman	Neutral
2024-10-02	Eingeleitet	RBC Capital Mkts	Outperform
2024-08-22	Eingeleitet	Morgan Stanley	Equal-Weight
2024-08-08	Eingeleitet	Canaccord Genuity	Buy
2024-05-30	Eingeleitet	Redburn Atlantic	Buy
2024-05-22	Hochstufung	Citigroup	Neutral → Buy
2024-04-29	Hochstufung	Wells Fargo	Equal Weight → Overweight
2024-04-25	Hochstufung	Leerink Partners	Market Perform → Outperform
2024-03-26	Hochstufung	Stifel	Hold → Buy
2023-08-04	Herabstufung	Citigroup	Buy → Neutral
2023-05-05	Herabstufung	BofA Securities	Neutral → Underperform
2023-04-24	Herabstufung	Raymond James	Outperform → Mkt Perform
2023-03-29	Eingeleitet	UBS	Neutral
2023-01-26	Eingeleitet	Wolfe Research	Peer Perform
2022-11-15	Hochstufung	Wells Fargo	Underweight → Equal Weight
2022-10-18	Eingeleitet	Barclays	Overweight
2022-10-12	Eingeleitet	Jefferies	Buy
2022-08-09	Herabstufung	Wells Fargo	Overweight → Underweight
2022-03-02	Fortgesetzt	BofA Securities	Neutral
2022-01-19	Hochstufung	Wells Fargo	Equal Weight → Overweight
2021-07-21	Fortgesetzt	Cowen	Outperform
2021-05-25	Eingeleitet	Barclays	Underweight
2020-12-15	Herabstufung	Wells Fargo	Overweight → Equal Weight
2020-08-20	Eingeleitet	Wells Fargo	Overweight
2020-07-31	Hochstufung	Guggenheim	Neutral → Buy
2020-07-06	Hochstufung	Citigroup	Neutral → Buy
2020-06-18	Bestätigt	Raymond James	Outperform
2020-04-24	Herabstufung	SVB Leerink	Outperform → Mkt Perform
2020-03-23	Herabstufung	Guggenheim	Buy → Neutral
2020-03-05	Eingeleitet	Citigroup	Neutral
2020-02-06	Eingeleitet	Raymond James	Outperform
2020-02-04	Herabstufung	Robert W. Baird	Outperform → Neutral
2019-10-18	Eingeleitet	Guggenheim	Buy
2019-10-04	Hochstufung	UBS	Neutral → Buy
2019-05-17	Bestätigt	BofA/Merrill	Neutral
2019-05-13	Eingeleitet	SVB Leerink	Outperform
2019-03-08	Eingeleitet	BMO Capital Markets	Outperform
2019-03-05	Bestätigt	BofA/Merrill	Neutral
2019-02-27	Bestätigt	Lake Street	Buy
2018-11-21	Hochstufung	Robert W. Baird	Neutral → Outperform
2018-09-26	Bestätigt	Dougherty & Company	Buy
2018-09-26	Bestätigt	Piper Jaffray	Overweight

Alle ansehen

Tandem Diabetes Care Inc Aktie (TNDM) Neueste Nachrichten

Mar 30, 2026

Tandem Diabetes Care Stock Hits Day Low Amid Price Pressure at $20.93 - Markets Mojo

Mar 30, 2026

Tandem Diabetes Care (TNDM) reports Q4 earnings: What key metrics have to say - MSN

Mar 30, 2026

Mar 29, 2026

Stock List: Research Stocks from Around the World - gurufocus.com

Mar 29, 2026

Tandem Diabetes and Roche Reach a Patent Settlement - MSN

Mar 29, 2026

Mar 27, 2026

Board asks shareholders to approve 3.26M-share increase; TNDM files proxy (TNDM) - Stock Titan

Mar 27, 2026

Tandem Diabetes Care (NASDAQ:TNDM) Trading Down 6.6%Time to Sell? - MarketBeat

Mar 27, 2026

Elanco, Tandem Diabetes, Fortrea, Natera, and Myriad Genetics Shares Plummet, What You Need To Know - TradingView

Mar 27, 2026

[SCHEDULE 13G/A] TANDEM DIABETES CARE INC Amended Passive Investment Disclosure - Stock Titan

Mar 27, 2026

Tandem Diabetes Care, Inc. Investigated by the Portnoy Law Firm - GlobeNewswire

Mar 27, 2026

Mizuho maintains Tandem Diabetes Care (TNDM) neutral recommendation - MSN

Mar 27, 2026

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Receives Consensus Rating of "Hold" from Analysts - MarketBeat

Mar 27, 2026

Mar 26, 2026

Assenagon Asset Management S.A. Invests $26.99 Million in Tandem Diabetes Care, Inc. $TNDM - MarketBeat

Mar 26, 2026

Mar 25, 2026

Strength seen in Tandem Diabetes Care (TNDM): Can its 9.1% jump turn into more strength? - msn.com

Mar 25, 2026

Mar 23, 2026